Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Notes Payables (2016 - 2021)

Adma Biologics (ADMA) has disclosed Notes Payables for 7 consecutive years, with $100.0 million as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Notes Payables changed N/A year-over-year to $100.0 million, compared with a TTM value of $100.0 million through Mar 2021, changed N/A, and an annual FY2020 reading of $100.0 million, up 37.93% over the prior year.
  • Notes Payables was $100.0 million for Q1 2021 at Adma Biologics, roughly flat from $100.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $100.0 million in Q4 2020 and bottomed at $6.7 million in Q1 2017.
  • Average Notes Payables over 5 years is $57.3 million, with a median of $72.5 million recorded in 2019.
  • The sharpest move saw Notes Payables tumbled 63.07% in 2017, then skyrocketed 141.67% in 2019.
  • Year by year, Notes Payables stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then soared by 141.67% to $72.5 million in 2019, then soared by 37.93% to $100.0 million in 2020, then changed by 0.0% to $100.0 million in 2021.
  • Business Quant data shows Notes Payables for ADMA at $100.0 million in Q1 2021, $100.0 million in Q4 2020, and $85.0 million in Q3 2020.